Regeneron’s inventory is having its worst day in 14 years after the failure of late-stage trial of its COPD remedy, after analysts had simply positioned a excessive chance of a constructive end result.
Source link
Regeneron dashes Wall Road’s hopes as COPD remedy trial suffers a failure
